Emergent Biosolutions (EBS) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/09/23
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Emergent BioSolutions Inc. for Potential Breaches of Fiduciary Duty By Its Board of DirectorsPRNewsWire • 08/08/23
Emergent BioSolutions Announces Strategic Steps to Strengthen Core Business and Financial PositionGlobeNewsWire • 08/08/23
Emergent BioSolutions Awarded 10-Year BARDA Contract Valued at up to a Maximum of $704 Million for Advanced Development and Procurement of Ebanga™ Treatment for EbolaGlobeNewsWire • 07/31/23
Emergent BioSolutions to Release Second Quarter 2023 Financial Results and Conduct Conference Call on August 8, 2023GlobeNewsWire • 07/25/23
Emergent BioSolutions Receives U.S. FDA Approval of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis UseGlobeNewsWire • 07/20/23
Why Is Emergent Biosolutions (EBS) Down 21.4% Since Last Earnings Report?Zacks Investment Research • 06/08/23
Emergent BioSolutions Finalizes Sale of Travel Health Business to Bavarian NordicGlobeNewsWire • 05/15/23
Bavarian Nordic Completes Acquisition of Travel Vaccine Portfolio from Emergent BioSolutionsGlobeNewsWire • 05/15/23
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 25, 2023 at 9:00am EDTGlobeNewsWire • 05/11/23
Emergent BioSolutions: A Turnaround In Sight With OTC Narcan Amidst Ongoing Opioid CrisisSeeking Alpha • 05/10/23